JP2018503687A - フルチカゾンプロピオン酸エステル及びサルメテロールキシナホ酸塩を含むドライパウダー吸入器 - Google Patents

フルチカゾンプロピオン酸エステル及びサルメテロールキシナホ酸塩を含むドライパウダー吸入器 Download PDF

Info

Publication number
JP2018503687A
JP2018503687A JP2017556791A JP2017556791A JP2018503687A JP 2018503687 A JP2018503687 A JP 2018503687A JP 2017556791 A JP2017556791 A JP 2017556791A JP 2017556791 A JP2017556791 A JP 2017556791A JP 2018503687 A JP2018503687 A JP 2018503687A
Authority
JP
Japan
Prior art keywords
dose
inhaler
fluticasone propionate
dry powder
port
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017556791A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018503687A5 (enExample
Inventor
ダルヴィ，ムクル
ティー，シーア，キー
Original Assignee
テバ ブランデッド ファーマシューティカル プロダクツ アール アンド ディー インコーポレイテッド
テバ ブランデッド ファーマシューティカル プロダクツ アール アンド ディー インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55443303&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2018503687(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by テバ ブランデッド ファーマシューティカル プロダクツ アール アンド ディー インコーポレイテッド, テバ ブランデッド ファーマシューティカル プロダクツ アール アンド ディー インコーポレイテッド filed Critical テバ ブランデッド ファーマシューティカル プロダクツ アール アンド ディー インコーポレイテッド
Publication of JP2018503687A publication Critical patent/JP2018503687A/ja
Publication of JP2018503687A5 publication Critical patent/JP2018503687A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0001—Details of inhalators; Constructional features thereof
    • A61M15/0005—Details of inhalators; Constructional features thereof with means for agitating the medicament
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0001—Details of inhalators; Constructional features thereof
    • A61M15/0005—Details of inhalators; Constructional features thereof with means for agitating the medicament
    • A61M15/0006—Details of inhalators; Constructional features thereof with means for agitating the medicament using rotating means
    • A61M15/0008—Details of inhalators; Constructional features thereof with means for agitating the medicament using rotating means rotating by airflow
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0001—Details of inhalators; Constructional features thereof
    • A61M15/0021—Mouthpieces therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. ventilators; Tracheal tubes
    • A61M16/10—Preparation of respiratory gases or vapours
    • A61M16/14—Preparation of respiratory gases or vapours by mixing different fluids, one of them being in a liquid phase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/06—Solids
    • A61M2202/064—Powder

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2017556791A 2015-01-20 2016-01-20 フルチカゾンプロピオン酸エステル及びサルメテロールキシナホ酸塩を含むドライパウダー吸入器 Pending JP2018503687A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562105479P 2015-01-20 2015-01-20
US62/105,479 2015-01-20
PCT/US2016/014072 WO2016118589A1 (en) 2015-01-20 2016-01-20 Dry powder inhaler comprising fluticasone propionate and salmeterol xinafoat

Publications (2)

Publication Number Publication Date
JP2018503687A true JP2018503687A (ja) 2018-02-08
JP2018503687A5 JP2018503687A5 (enExample) 2020-03-12

Family

ID=55443303

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017556791A Pending JP2018503687A (ja) 2015-01-20 2016-01-20 フルチカゾンプロピオン酸エステル及びサルメテロールキシナホ酸塩を含むドライパウダー吸入器

Country Status (19)

Country Link
US (2) US9415008B2 (enExample)
EP (1) EP3247331A1 (enExample)
JP (1) JP2018503687A (enExample)
KR (1) KR20170103975A (enExample)
CN (1) CN107530357A (enExample)
AR (1) AR104771A1 (enExample)
AU (2) AU2016209363B2 (enExample)
BR (1) BR112017015353A2 (enExample)
CA (1) CA2974125A1 (enExample)
CL (1) CL2017001859A1 (enExample)
CO (1) CO2017008395A2 (enExample)
EA (1) EA201791632A1 (enExample)
HK (1) HK1245125A1 (enExample)
IL (1) IL253499A0 (enExample)
MA (1) MA41378A (enExample)
MX (2) MX383344B (enExample)
PE (1) PE20171258A1 (enExample)
TW (1) TW201628607A (enExample)
WO (1) WO2016118589A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160243320A1 (en) * 2013-10-07 2016-08-25 Teva Branded Pharmaceutical Products R&D, Inc. Dry powder inhaler
MA41378A (fr) * 2015-01-20 2017-11-28 Teva Branded Pharmaceutical Prod R & D Inc Inhalateur de poudre sèche comprenant du propionate de fluticasone et du xinafoate de salmétérol
ES2884802T3 (es) * 2016-11-18 2021-12-13 Norton Waterford Ltd Dispositivo de administración de fármacos con componentes electrónicos
CN110201278B (zh) * 2018-02-28 2021-07-30 张江 用于吸入给药的药盒和吸入给药组合结构
CN110201280B (zh) * 2018-02-28 2021-07-30 张江 用于吸入给药装置的吸嘴和吸入给药装置
CN110201281B (zh) * 2018-02-28 2021-08-06 张江 吸入给药装置和吸入给药组合结构
CN110064110A (zh) * 2019-05-29 2019-07-30 上海理工大学 一种容积旋钮式干粉储存吸入装置
GB2585206B (en) * 2019-07-01 2021-08-11 Merxin Ltd Portable inhaler

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004501685A (ja) * 2000-06-23 2004-01-22 ノートン　ヘルスケアー　リミテッド 薬剤吸入器
JP2005508963A (ja) * 2001-10-12 2005-04-07 グラクソ　グループ　リミテッド 喘息を治療するためのサルメテロールとフルチカゾンプロピオネートを含む医薬の組み合せ
WO2015054124A2 (en) * 2013-10-07 2015-04-16 Teva Branded Pharmaceutical Products R&D, Inc. Dry powder inhaler
JP2016520581A (ja) * 2013-05-03 2016-07-14 ダウ グローバル テクノロジーズ エルエルシー 平衡制約反応のためのプロセス

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5270305A (en) * 1989-09-08 1993-12-14 Glaxo Group Limited Medicaments
US6395300B1 (en) 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
GB0008660D0 (en) * 2000-04-07 2000-05-31 Arakis Ltd The treatment of respiratory diseases
AR028747A1 (es) 2000-06-23 2003-05-21 Norton Health Care Ltd Desaglomerador para inhalador de polvo seco accionado por la respiracion, un inhalador de polvo seco y un metodo de desaglomeracion de polvo seco.
AR030516A1 (es) * 2000-08-31 2003-08-20 Glaxo Group Ltd Uso de una combinacion de salmeterol y fluticasona
DK1337240T4 (en) * 2000-11-30 2015-01-05 Vectura Ltd A process for the preparation of particles for use in a pharmaceutical composition
CN1694689A (zh) 2002-09-30 2005-11-09 阿库斯菲尔公司 供吸入的缓释多孔微粒
US9114081B2 (en) * 2007-05-07 2015-08-25 Insmed Incorporated Methods of treating pulmonary disorders with liposomal amikacin formulations
TWI792140B (zh) * 2009-05-29 2023-02-11 美商沛爾醫療股份有限公司 用於經由呼吸道遞送二或更多種活性藥劑的組成物、方法與系統
CN102573886A (zh) * 2009-09-17 2012-07-11 相互制药公司 用抗病毒剂治疗哮喘的方法
GB0919465D0 (en) * 2009-11-06 2009-12-23 Norton Healthcare Ltd Airflow adaptor for a breath-actuated dry powder inhaler
PL2436414T3 (pl) * 2010-05-18 2015-10-30 Ivax Pharmaceuticals Ireland Licznik dawek do inhalatorów i inhalator
WO2011145109A1 (en) 2010-05-20 2011-11-24 Sun Pharma Advanced Research Company Ltd., Dry powder inhalation composition
KR20130140358A (ko) * 2012-06-14 2013-12-24 한미약품 주식회사 살메테롤 지나포산염, 플루티카손 프로피오네이트 및 티오트로피움 브로마이드를 포함하는 흡입 제형용 건조 분말 및 이의 제조방법
AU2014261539A1 (en) * 2013-04-29 2015-12-10 Sanofi Sa Inhalable pharmaceutical compositions and the inhaler devices containing them
JP6653324B2 (ja) * 2014-10-16 2020-02-26 テバ ブランデッド ファーマシューティカル プロダクツ アール アンド ディー インコーポレイテッド 乾燥粉末製剤
MA41378A (fr) * 2015-01-20 2017-11-28 Teva Branded Pharmaceutical Prod R & D Inc Inhalateur de poudre sèche comprenant du propionate de fluticasone et du xinafoate de salmétérol

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004501685A (ja) * 2000-06-23 2004-01-22 ノートン　ヘルスケアー　リミテッド 薬剤吸入器
JP2005508963A (ja) * 2001-10-12 2005-04-07 グラクソ　グループ　リミテッド 喘息を治療するためのサルメテロールとフルチカゾンプロピオネートを含む医薬の組み合せ
JP2016520581A (ja) * 2013-05-03 2016-07-14 ダウ グローバル テクノロジーズ エルエルシー 平衡制約反応のためのプロセス
WO2015054124A2 (en) * 2013-10-07 2015-04-16 Teva Branded Pharmaceutical Products R&D, Inc. Dry powder inhaler

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GLAXOSMITHKLINE, ADVAIR DISKUS LABEL[ONLINE](RETRIEVED ON 2019 JULY 29), JPN6019030058, 2008, US, pages 1 - 62, ISSN: 0004439716 *
J THORAC DIS., vol. 5(4), JPN6019030060, 2013, pages 393 - 399, ISSN: 0004439717 *

Also Published As

Publication number Publication date
HK1245125A1 (zh) 2018-08-24
US9415008B2 (en) 2016-08-16
KR20170103975A (ko) 2017-09-13
AU2016209363B2 (en) 2021-02-04
MX2017009122A (es) 2017-10-12
BR112017015353A2 (pt) 2018-01-16
US20160206559A1 (en) 2016-07-21
CA2974125A1 (en) 2016-07-28
PE20171258A1 (es) 2017-08-28
AR104771A1 (es) 2017-08-16
WO2016118589A1 (en) 2016-07-28
EP3247331A1 (en) 2017-11-29
CN107530357A (zh) 2018-01-02
EA201791632A1 (ru) 2017-12-29
CL2017001859A1 (es) 2018-04-06
MX2021006751A (es) 2021-07-15
CO2017008395A2 (es) 2018-01-05
US20180015035A1 (en) 2018-01-18
AU2021202784A1 (en) 2021-05-27
MX383344B (es) 2025-03-13
IL253499A0 (en) 2017-09-28
MA41378A (fr) 2017-11-28
TW201628607A (zh) 2016-08-16
AU2016209363A1 (en) 2017-08-24

Similar Documents

Publication Publication Date Title
JP6543620B2 (ja) ドライパウダー吸入器
DK3079744T3 (en) dry powder inhaler
JP2018503687A (ja) フルチカゾンプロピオン酸エステル及びサルメテロールキシナホ酸塩を含むドライパウダー吸入器
JP6946363B2 (ja) 吸入可能な薬剤
HK1242605A1 (en) Dry powder inhaler comprising fluticasone propionate and salmeterol xinafoat
HK1219444B (zh) 干粉吸入器
NZ718315B2 (en) Dry powder inhaler
HK1227340B (zh) 乾粉吸入器

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180921

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190620

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190807

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20191105

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200106

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200129

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20200129

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200701

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210210